Liquid Biopsies

FoundationOne Liquid CDx Granted New and Expanded FDA Indications in Various Solid Tumors

October 28, 2020

The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.

Positive Tepotinib Data Underscore Value of Liquid Biopsies in Non-Small Cell Lung Cancer

July 01, 2020

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.

Microfluidic Platforms Help Isolate Rare Cells in Leukemias

May 17, 2020

In an interview with Targeted Oncology, Steve A. Soper, PhD, discussed microfluidic platforms for use in isolating circulating leukemia cells and plasma cells in patients with acute lymphoblastic leukemia and acute myeloid leukemia.

Liquid Biopsy Assay Detects 50+ Types of Cancer and Identifies Cancer Origin in Tissue

April 06, 2020

The first liquid biopsy assay, a blood test, to detect over 50 types of cancer has been developed and is able to identify in which part of the body that the cancer originated in, based on findings from a prospective multicenter case-control observational trial, the CCGA study published in Annals of Oncology. The test also identified cancer prior to symptoms in most patients, according to a press release.

Investigators Gain Actionable Information Without Tumor Tissue

March 31, 2020

Use of the liquid biopsy assay MSK-ACCESS has led to detection of actionable genetic variants in 40% of tumor samples, offering an attrac­tive alternative to invasive tumor biopsies in patients with no available tissue for testing.